Wave Life Sciences Ltd. (NASDAQ:WVE) CFO Kyle Moran Sells 15,630 Shares

Wave Life Sciences Ltd. (NASDAQ:WVE) CFO Kyle Moran sold 15,630 shares of the business’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $6.17, for a total transaction of $96,437.10. Following the completion of the sale, the chief financial officer now owns 33,921 shares in the company, valued at approximately $209,292.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Wave Life Sciences Price Performance

Wave Life Sciences stock opened at $5.91 on Friday. Wave Life Sciences Ltd. has a 1-year low of $3.15 and a 1-year high of $7.67. The company’s 50-day moving average is $5.16 and its 200 day moving average is $5.22.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $29.06 million during the quarter, compared to analysts’ expectations of $23.30 million. During the same period last year, the company earned ($0.47) earnings per share. On average, equities research analysts anticipate that Wave Life Sciences Ltd. will post -0.94 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Leerink Partnrs upgraded shares of Wave Life Sciences from a “market perform” rating to an “outperform” rating in a research note on Tuesday, December 19th. SVB Leerink upgraded shares of Wave Life Sciences from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $5.00 to $12.00 in a research note on Tuesday, December 19th. Truist Financial reiterated a “buy” rating and issued a $17.00 price target on shares of Wave Life Sciences in a research note on Monday, April 1st. HC Wainwright boosted their price target on shares of Wave Life Sciences from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, March 7th. Finally, StockNews.com cut shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 18th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Institutional Trading of Wave Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WVE. Wellington Management Group LLP grew its stake in Wave Life Sciences by 4.3% in the 3rd quarter. Wellington Management Group LLP now owns 264,885 shares of the company’s stock worth $1,523,000 after acquiring an additional 10,830 shares in the last quarter. Newtyn Management LLC grew its stake in Wave Life Sciences by 2.0% in the 3rd quarter. Newtyn Management LLC now owns 510,000 shares of the company’s stock worth $2,932,000 after acquiring an additional 10,000 shares in the last quarter. SG Americas Securities LLC bought a new position in Wave Life Sciences in the 3rd quarter worth about $149,000. Kraematon Investment Advisors Inc. bought a new position in Wave Life Sciences in the 4th quarter worth about $237,000. Finally, Jump Financial LLC bought a new position in Wave Life Sciences in the 3rd quarter worth about $135,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.